18FDG PET/CT in Primary Cutaneous Diffuse Large B-Cell Lymphoma Leg Type.


Journal

Clinical nuclear medicine
ISSN: 1536-0229
Titre abrégé: Clin Nucl Med
Pays: United States
ID NLM: 7611109

Informations de publication

Date de publication:
May 2020
Historique:
pubmed: 27 3 2020
medline: 28 8 2020
entrez: 27 3 2020
Statut: ppublish

Résumé

An 86-year-old woman was referred for a rare but aggressive subtype of primary cutaneous lymphoma of the right lower limb: diffuse large B-cell lymphoma leg type. Initial evaluation by whole-body F-FDG PET/CT showed intense hypermetabolic activity of multiple cutaneous and subcutaneous nodules of the distal third of the right leg. Follow-up evaluations by F-FDG PET/CT showed complete response after 4 and 8 cycles of appropriate rituximab combination with polychemotherapy. Although no specific recommendations are available, our case stresses the major role of F-FDG PET/CT for initial extension and treatment response evaluation in clinical practice of primary cutaneous diffuse large B-cell lymphoma leg type.

Identifiants

pubmed: 32209875
doi: 10.1097/RLU.0000000000002995
pii: 00003072-202005000-00019
doi:

Substances chimiques

Fluorodeoxyglucose F18 0Z5B2CJX4D
Rituximab 4F4X42SYQ6

Types de publication

Case Reports Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

403-404

Références

Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood. 2005;105:3768–3785.
Willemze R, Cerroni L, Kempf W, et al. The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas. Blood. 2019;133:1703–1714.
Wilcox RA. Cutaneous B-cell lymphomas: 2019 update on diagnosis, risk stratification, and management. Am J Hematol. 2018;93:1427–1430.
Grange F, Beylot-Barry M, Courville P, et al. Primary cutaneous diffuse large B-cell lymphoma, leg type: clinicopathologic features and prognostic analysis in 60 cases. Arch Dermatol. 2007;143:1144–1150.
Athalye L, Nami N, Shitabata P. A rare case of primary cutaneous diffuse large B-cell lymphoma, leg type. Cutis. 2018;102:E31–E34.
Sokol L, Naghashpour M, Glass LF. Primary cutaneous B-cell lymphomas: recent advances in diagnosis and management. Cancer Control. 2012;19:236–244.
Pham-Ledard A, Prochazkova-Carlotti M, Andrique L, et al. Multiple genetic alterations in primary cutaneous large B-cell lymphoma, leg type support a common lymphomagenesis with activated B-cell–like diffuse large B-cell lymphoma. Mod Pathol. 2014;27:402–411.
Pham-Ledard A, Beylot-Barry M, Barbe C, et al. High frequency and clinical prognostic value of MYD88 L265P mutation in primary cutaneous diffuse large B-cell lymphoma, leg-type. JAMA Dermatol. 2014;150:1173–1179.
Grange F, Joly P, Barbe C, et al. Improvement of survival in patients with primary cutaneous diffuse large B-cell lymphoma, leg type, in France. JAMA Dermatol. 2014;150:535–541.
Grange F, D'Incan M, Ortonne N, et al. Management of cutaneous B-cell lymphoma: recommendations of the French cutaneous lymphoma study group. Ann Dermatol Venereol. 2010;137:523–531.
Qiu L, Tu G, Li J, et al. The role of 18F-FDG PET and PET/CT in the evaluation of primary cutaneous lymphoma. Nucl Med Commun. 2017;38:106–116.
Spaccarelli N, Gharavi M, Saboury B, et al. Role of (18)F-fluorodeoxyglucose positron emission tomography imaging in the management of primary cutaneous lymphomas. Hell J Nucl Med. 2014;17:78–84.
Samarghandi A, Gru AA, Natwa M, et al. (18)FDG PET/CT appearance in primary cutaneous diffuse large B-cell lymphoma, leg type. Clin Nucl Med. 2015;40:506–508.
Ni C, Lewis M, Berenji G. FDG PET/CT findings in primary diffuse large B-cell lymphoma, leg type. Clin Nucl Med. 2016;41:65–68.

Auteurs

Sébastien Dejust (S)

From the Unité de Médecine Nucléaire, Institut Godinot.

Eric Durot (E)

Service d'Hématologie clinique CHU Robert Debré et UFR de Médecine.

Florent Grange (F)

Service de Dermatologie, CHU Robert Debré, Reims, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH